Aspira Women’s Health (AWH) – Research Analysts’ Weekly Ratings Updates

Aspira Women’s Health (NASDAQ: AWH) recently received a number of ratings updates from brokerages and research firms:

• 6/26/2024 – Aspira Women’s Health is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 6/20/2024 – Aspira Women’s Health is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 6/14/2024 – Aspira Women’s Health is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 6/8/2024 – Aspira Women’s Health is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 6/2/2024 – Aspira Women’s Health is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 5/27/2024 – Aspira Women’s Health is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 5/21/2024 – Aspira Women’s Health is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 5/15/2024 – Aspira Women’s Health is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 5/9/2024 – Aspira Women’s Health is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 5/3/2024 – Aspira Women’s Health is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 4/27/2024 – Aspira Women’s Health is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Aspira Women’s Health Price Performance

Shares of Aspira Women’s Health stock opened at $1.25 on Wednesday. Aspira Women’s Health Inc. has a 1-year low of $1.18 and a 1-year high of $6.75. The business’s fifty day moving average price is $2.57 and its two-hundred day moving average price is $3.46. The company has a market capitalization of $15.56 million, a P/E ratio of -0.86 and a beta of 1.50.

Aspira Women’s Health (NASDAQ:AWH) last posted its quarterly earnings data on Tuesday, May 21st. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Aspira Women’s Health had a negative return on equity of 1,099.32% and a negative net margin of 163.95%. The company had revenue of $2.15 million during the quarter, compared to analyst estimates of $2.10 million. During the same period in the previous year, the company earned ($10.94) EPS. On average, research analysts expect that Aspira Women’s Health Inc. will post -1.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aspira Women’s Health

Several hedge funds have recently modified their holdings of the company. Northeast Financial Consultants Inc acquired a new stake in shares of Aspira Women’s Health in the third quarter valued at $126,000. Quantum Private Wealth LLC raised its position in Aspira Women’s Health by 76.8% in the fourth quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock worth $205,000 after acquiring an additional 21,788 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. lifted its holdings in Aspira Women’s Health by 39.0% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 125,374 shares of the company’s stock valued at $672,000 after acquiring an additional 35,177 shares during the last quarter. 12.19% of the stock is currently owned by institutional investors and hedge funds.

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.